RELATED PRODUCTS NOT AVAILABLE
true
Support
Singapore (Greater Asia Head Office)
+65 6664 2700
bd_sea@bd.com
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Address
2 International Business Park Road, #08-08 The Strategy, Singapore 609930
- Overview
- Products & Accessories
- EIFU & Resources
false
Support risk stratification
Extended genotyping supports risk stratification and persistence monitoring to guide patient management1-5
Adapt to evolving screening guidelines
The BD Onclarity™ HPV Assay offers the flexibility you need to adapt to changing screening guidelines and evolving patient management guidance.
Enhance patient management
Make more informed decisions with the extended genotyping information you need to assess each patient’s risk for confident follow-up decisions1-5
Genotype reporting
The BD Onclarity™ HPV assay reports individual results for 6 of the 14 high-risk genotypes and grouped results for the remaining 8 high-risk genotypes.12
Providing you with advanced accurate, timely detection and actionable HPV genotyping so you can make more informed decisions.
- The BD Onclarity™ HPV assay is designed to minimize the risk of false-negative results by:
- Including an internal cellular control, ensuring cellular material is present
- Targeting the E6/E7 region of the HPV viral genome rather than the L1 region, which can be deleted during HPV DNA integration13
- The BD Onclarity™ HPV assay is designed to minimize the rise of false-positive results by lacking cross-reactivity with low-risk HPV types12
- Make more informed decisions with the extended genotyping information you need to assess each patient’s risk for confident follow-up decisions1-5
true
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
true
- Stoler MH et al. Gynecol Oncol. 2019;153(1):26–33
- Bonde J et al. Int J Cancer. 2019; doi:10.1002/ijc.32291
- Elfgren K et al. Am J Obstet Gynecol. 2017;216(3):264.e1–264.e7.
- Radley D et al. Hum Vaccin Immunother. 2016;12(3):768–772.
- Bottari F et al. J Low Genit Tract Dis. 2019;23(1):39–42.
- WHO RHR. Cervical cancer, human papillomavirus (HPV), and HPV vaccines—key points for policy-makers and health professionals. WHO; 2007.
- Oliver SE et al. J Infect Dis. 2017;216(5):594–603.
- Drolet M et al. Lancet Infect Dis. 2015;15(5):565–580.
- Garland SM et al. Clin Infect Dis. 2016;63(4):519–527.
- Schiffman M et al. Gynecol Oncol. 2015;138(3):573–578.
- Schiffman M et al. Int J Cancer. 2016;139(11):2606–2615.
- BD OnclarityTM HPV Assay US Package Insert (8089899)
- Tjalma WAA et al. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):45–46.
true